Edition:
United States

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

17.47USD
3:59pm EST
Change (% chg)

$-0.72 (-3.96%)
Prev Close
$18.19
Open
$18.13
Day's High
$18.13
Day's Low
$17.34
Volume
83,399
Avg. Vol
82,237
52-wk High
$19.82
52-wk Low
$13.55

Summary

Name Age Since Current Position

David Phillips

79 2018 Chairman of the Board

John Kenny

49 2017 Chief Executive Officer, Director

Melissa Lueke

54 2009 Chief Financial Officer, Executive Vice President, Secretary

Marco Calzavara

63 2011 President and Managing Director of Meridian Bioscience Europe

Lawrence Baldini

58 2016 Executive Vice President and President - Global Operations

Susan Rolih

68 2013 Executive Vice President - Regulatory & Quality Systems

Amy Winslow

46 2016 Executive Vice President, President and Chief Executive Officer - Magellan

James Anderson

75 2009 Independent Director

Dwight Ellingwood

65 2014 Independent Director

John McIlwraith

58 2015 Independent Director

John Rice

68 2017 Independent Director

Catherine Sazdanoff

61 2015 Independent Director

Felicia Williams

52 2018 Independent Director

Biographies

Name Description

David Phillips

Mr. David C. Phillips serves as Chairman of the Board of the Company, effective September 30, 2018. He serves as Chairman of the Audit Committee and Lead Director. Mr. Phillips spent 32 years with Arthur Andersen LLP. His service with this firm included several managing partner leadership positions. After retiring from Arthur Andersen in 1994, Mr. Phillips became Chief Executive Officer of Downtown Cincinnati, Inc., which is responsible for economic revitalization of Downtown Cincinnati. Mr. Phillips retired from DCI in 1999 to devote full time to Cincinnati Works, Inc., an organization dedicated to reducing the number of people living below the poverty level by assisting them to strive towards self-sufficiency through work, and his financial consulting services. Mr. Phillips has also served as a director of Cintas Corporation, retiring in 2012, and as a director of Summit Mutual Funds, a registered investment company, through 2009. The Board believes that Mr. Phillips’ years of service as a certified public accountant and trusted advisor to his clients and business owners, which qualify him as an “audit committee financial expert” under SEC guidelines, give him significant experience in preparing, auditing, analyzing and evaluating financial statements and dealing with complex accounting and business issues, all of which is valuable to Meridian.

John Kenny

Mr. John (Jack) P. Kenny serves as Chief Executive Officer, Director of the company. Before joining Meridian, Mr. Kenny served as Senior Vice President and General Manager, North America, with Siemens Healthcare, a position he held from October 2014 to May 2017. From June 2012 through October 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, Diagnostic Systems. Prior to June 2012, Mr. Kenny held executive roles at Danaher Corporation and Quest Diagnostics. Mr. Kenny’s experience as a key executive leader within large public companies in the health care and medical device industry, as well as his ongoing insights into Meridian’s business and operations, makes him a valuable member of the Board.

Melissa Lueke

Ms. Melissa A. Lueke serves as Chief Financial Officer, Executive Vice President, Secretary of the Company. She has more than 30 years of finance experience and joined Meridian in January 1999 as U.S. Area Controller. She was appointed Vice President, Chief Financial Officer and Secretary in January of 2001, and was appointed Executive Vice President in December of 2009. Before joining Meridian, Ms. Lueke was Senior Audit Manager at Arthur Andersen LLP.

Marco Calzavara

Mr. Marco G. Calzavara serves as President and Managing Director of Meridian Bioscience Europe of Company. He has more than 24 years in the European biotech industry. Mr. Calzavara was founder and CEO of the Bioline Group which manufactures reagents for molecular biology. Bioline was acquired by Meridian in July 2010. In April 2011, Marco Calzavara was appointed President of Meridian Bioscience Europe.

Lawrence Baldini

Mr. Lawrence J. Baldini is Executive Vice President and President - Global Operations of the Company. He has more than 36 years of experience in the industry and was appointed Executive Vice President and President, Global Operations in 2016, Executive Vice President of Operations and Information Systems in 2005, and had been the Vice President of Operations of Meridian Bioscience, Inc. since 2001. Before joining Meridian, Mr. Baldini was Director of Operations (Sensory Systems) at Instrumentation Laboratories, where he previously held the title of Operations Manager and Facilities Manager.

Susan Rolih

Ms. Susan D. Rolih is no longer Executive Vice President - Regulatory & Quality Systems of the Company., effective November 30, 2018. She has more than 35 years of experience in the industry and was appointed Senior Vice President, Regulatory Affairs and Quality Assurance in 2008. She had been Vice President Regulatory Affairs and Quality Assurance since 2001. Before joining Meridian, Ms. Rolih was Corporate Vice President – Regulatory Affairs and Quality Assurance at Immucor, Inc. where she previously held titles of Vice President - Regulatory Affairs and Quality Assurance, and Vice President-Technical Services.

Amy Winslow

Ms. Amy M. Winslow serves as Executive Vice President of the company and President and Chief Executive Officer - Magellan. Amy M. Winslow was appointed Executive Vice President & President and Chief Executive Officer of Magellan in March 2016 at the time Meridian acquired Magellan, having served as President and Chief Executive Officer of Magellan since October 2011. With over 20 years of experience in health care, prior to joining Magellan, Ms. Winslow served as President of MW Advisory (June 2004 – October 2011) and Vice President, Marketing for Athena Diagnostics (August 1999 – June 2004).

James Anderson

Mr. James M. Anderson serves as Independent Director of Company. He currently serves as President Emeritus of Cincinnati Children’s Hospital Medical Center (“CCHMC”), after having served as advisor to the President of CCHMC from January 2010 through June 30, 2017 and as President and Chief Executive Officer of CCHMC from 1996 through 2009. From 2006 to 2014, he served as a director of Ameritas Mutual Holding Company and has also served as Chairman of the Board of the Cincinnati Branch of the Federal Reserve Bank of Cleveland, retiring in 2012. Prior to joining the staff of CCHMC, Mr. Anderson was a partner in the general corporate law department at Taft, Stettinius & Hollister for 24 years (1968-1977; 1982-1996) and president of U.S. operations at Xomox Corporation, a publicly-traded manufacturer of specialty process controls (1977-1982). Mr. Anderson has also served as director of Gateway Investment Advisors (1997-2008). The Board believes that Mr. Anderson’s corporate legal experience and his experience as CEO of a large health care organization have given him a wealth of insight into various corporate governance and business management issues, which, along with his status as an independent Director, make him an integral member of the Board.

Dwight Ellingwood

Mr. Dwight E. Ellingwood serves as Independent Director of Company. He serves as Chairman of the Nominating and Corporate Governance Committee. With 35 years of experience in health care strategy, planning, commercialization and marketing, he is currently the President of D.E.E. Strategy Consulting, LLC, partnering with leadership in health care, education and the community to develop strategy, relationships and innovative approaches to growth, organization transformation and collaborations. Mr. Ellingwood previously served as Senior Vice President of Strategy, Communications and Public Affairs for TriHealth in Cincinnati, Ohio (November 2014 – July 2016; and as the Lead Executive for the Collective Impact on Health, The Health Collaborative (January 2014 – November 2014). From 1997 through 2013, Mr. Ellingwood served as Senior Vice President, Planning and Business Development for Cincinnati Children’s Hospital Medical Center. The Board believes that the Company will benefit greatly from Mr. Ellingwood’s extensive experience in the health care industry.

John McIlwraith

Mr. John C. McIlwraith serves as Independent Director of Meridian Bioscience, Inc. He co-founded Allos Ventures, a venture capital firm, in March 2010 and has served as a Managing Director there since that time. Prior to founding Allos Ventures, Mr. McIlwraith was a Managing Director of Blue Chip Venture Company, a Cincinnati-based venture capital and private equity firm, which he joined in 1997. He has served on the board of directors of more than 20 health care or information technology companies. Prior to 1997, Mr. McIlwraith served as Senior Vice President of Strategic Planning and General Counsel of publicly-traded Quantum Health Resources, Inc., and was a partner in the Jones Day law firm. The Board believes that Mr. McIlwraith’s years of experience with an extensive number of companies, including health care companies, render his service on the Board valuable to Meridian.

John Rice

Dr. John McCune Rice Jr, Ph.D. serves as Independent Director of the Company. John M. Rice is the founder, and since 2003 has been the Managing Partner of Triathlon Medical Venture Partners, a venture capital firm that invests equity capital in early and expansion stage life science companies. Since 2014, Dr. Rice has also served as the Director of Life Sciences at CincyTech, a firm that provides advice and capital to entrepreneurs and helps research institutions commercialize technology through startups. In addition, Dr. Rice has served on the board of directors of several privately-held health care companies. The Board believes that Dr. Rice’s years of experience with a number of companies operating in the health care and related industries, as well as extensive experience within the capital markets, will prove extremely valuable to Meridian.

Catherine Sazdanoff

Ms. Catherine Ann Sazdanoff serves as Independent Director of Meridian Bioscience, Inc. She currently serves as Chief Business Officer of Strata Oncology, Inc., a precision medicine company providing no-cost tumor sequencing to advanced cancer patients and a portfolio of matching clinical trials, having joined Strata in May 2016. Since May 2016, she has also been a member of the Advisory Board of Neurocern, Inc., a privately-held dementia management system company. Immediately prior to joining Strata, Ms. Sazdanoff held the position of CEO and President of Sazdanoff Consulting LLC, specializing in business development, management and strategy consulting (January 2015 – May 2016). In addition, from January 2015 to March 2016, she served as Strategic Advisor to mProve Health LLC, a mobile health technology company located in Arlington, Virginia. From 2006 to 2015, Ms. Sazdanoff held a number of executive positions with Takeda Pharmaceutical International, Inc. (“Takeda”), a wholly-owned subsidiary of Japanese-based Takeda Pharmaceutical Corporation, including Vice President, Head of Corporate Projects (2012-2015), VP, Global Business Development (2011-2013) and VP, Corporate Development (2010-2011). Ms. Sazdanoff’s time at Takeda was preceded by approximately 22 years with Abbott Laboratories, where she held numerous executive positions. The Board believes that Ms. Sazdanoff’s years of experience in the pharmaceutical and medical diagnostics industries will make her service on the Board valuable to Meridian.

Felicia Williams

Ms. Felicia Williams is Independent Director of the Company. She has served as Executive Vice President, Controller and Enterprise Risk Officer at Macy's Inc. since June 2016. Previously she had served as Senior Vice President, Finance and Risk Management at Macy's from February 2011 through June 2016; and in other finance, treasury, risk management and internal audit capacities since joining the Company in June 2004. Prior to her time at Macy's, Ms. Williams served in various financial positions at the Coca-Cola Hellenic Bottling Company and The Coca-Cola Company from June 1994 through June 2004.

Basic Compensation